Status:
COMPLETED
LncRNA Nicotinamide Nucleotide Transhydrogenase-Antisense RNA1 NNT-AS1 in CRC
Lead Sponsor:
Ain Shams University
Conditions:
Colorectal Cancer
Eligibility:
All Genders
24-76 years
Brief Summary
The current study will compare the blood expression level of lncRNA NNT-AS1 and hsa-miR-485-5p, as well as heat shock protein 90 (HSP90) serum levels in both healthy and CRC Egyptian patients' cohort ...
Detailed Description
Colorectal cancer (CRC) is a heterogeneous malignancy that affects the colon and rectum. It is the third most prevalent and lethal malignancy, with roughly 1.9 million new cases and nearly 9.4% of can...
Eligibility Criteria
Inclusion
- CRC diagnosed patients that is clinically confirmed by colonoscopy, abdominal radio-imaging, and histopathologicaly.
Exclusion
- individuals receiving chemotherapy, radiation, or undergone surgery
- patients with blood disorders
- patients with any cancer other than CRC.
- Individuals with inadequate data or missing histopathological diagnoses
- distant metastases
Key Trial Info
Start Date :
October 1 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 1 2021
Estimated Enrollment :
88 Patients enrolled
Trial Details
Trial ID
NCT06531902
Start Date
October 1 2020
End Date
June 1 2021
Last Update
August 1 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Faculty of Pharmacy, Ain Shams University, Advanced Biochemistry Research Lab
Cairo, Egypt, 11566